Tectonic Therapeutic Completes Enrollment For The APEX Trial, A 24-Week Phase 2 Clinical Trial Evaluating The Safety And Efficacy Of TX45 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction; APEX Phase 2 Trial Enrolled 191 Patients Across 14 Countries, With ~72% Of Patients In The Enriched Population Of CpcPH With A Pulmonary Vascular Resistance >3 WU At Baseline